SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per attached letter.04-12-2023
04-12-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on December 4, 2023, with reference to Movement in Volume.The reply is awaited.04-12-2023
Glenmark, Sun Pharma recall drugs in the US over labelling and manufacturing concerns, confirms USFDA
Glenmark Pharmaceuticals recalled 37,200 bottles of Indomethacin capsules and Sun Pharma recalled 2016 bottles of buPROPion Hydrochloride Extended-Release Tablets.04-12-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per attached letter.30-11-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting.16-11-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q2FY24 Earnings Call Transcript08-11-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per the attached letter.08-11-2023
Buy Sun Pharmaceutical Industries; target of Rs 1280: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1280 in its research report dated November 02, 2023.06-11-2023
Sun Pharma share price rises as Q2 results surpass street estimates; here's why brokerages are bullish on the stock
Sun Pharma shares rise after Q2 results beat estimates on profit and revenue front. Brokerages maintain 'buy' rating for Sun Pharma.02-11-2023